Forge Biologics, Author at Forge Biologics - Page 3 of 12

Labcorp and Forge Biologics Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration 

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Labcorp and Forge Biologics Announce Strategic AAV Gene Therapy Development and Manufacturing Collaboration¬†

Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Forge Biologics Receives Qualified Person (QP) Declaration to Manufacture AAV Gene Therapies to Support European Clinical Programs

Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium

Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development

Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Manufacturing gene therapies for life Forge is a gene therapy development engine, enabling access to life-changing discoveries by bringing them […]

Read More… from Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership